Pinnacle Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.02M | Sell |
10,694
-509
| -5% | -$89K | 0.03% | 396 |
|
|
2025
Q4 | $1.9M | Buy |
11,203
+83
| +0.7% | +$12.7K | 0.02% | 401 |
|
|
2025
Q3 | $1.47M | Buy |
11,120
+312
| +3% | +$37.4K | 0.02% | 446 |
|
|
2025
Q2 | $1.15M | Buy |
10,808
+325
| +3% | +$35.3K | 0.02% | 477 |
|
|
2025
Q1 | $1.3M | Sell |
10,483
-100
| -0.9% | -$13K | 0.02% | 443 |
|
|
2024
Q4 | $1.3M | Buy |
10,583
+322
| +3% | +$38K | 0.02% | 437 |
|
|
2024
Q3 | $1.26M | Sell |
10,261
-77
| -0.7% | -$8.44K | 0.02% | 428 |
|
|
2024
Q2 | $1.1M | Sell |
10,338
-33
| -0.3% | -$3.63K | 0.02% | 451 |
|
|
2024
Q1 | $1.25M | Buy |
10,371
+110
| +1% | +$13.5K | 0.02% | 447 |
|
|
2023
Q4 | $1.26M | Sell |
10,261
-326
| -3% | -$40.7K | 0.02% | 435 |
|
|
2023
Q3 | $1.37M | Buy |
10,587
+238
| +2% | +$31.7K | 0.03% | 411 |
|
|
2023
Q2 | $1.28M | Buy |
10,349
+1,308
| +14% | +$176K | 0.02% | 430 |
|
|
2023
Q1 | $1.32M | Buy |
9,041
+3,561
| +65% | +$527K | 0.03% | 368 |
|
|
2022
Q4 | $873K | Buy |
5,480
+5
| +0.1% | +$733 | 0.02% | 415 |
|
|
2022
Q3 | $730K | Sell |
5,475
-150
| -3% | -$22.8K | 0.02% | 445 |
|
|
2022
Q2 | $878K | Sell |
5,625
-185
| -3% | -$28.5K | 0.02% | 431 |
|
|
2022
Q1 | $904K | Buy |
5,810
+3,930
| +209% | +$570K | 0.02% | 463 |
|
|
2021
Q4 | $240K | Buy |
1,880
+141
| +8% | +$18.5K | ﹤0.01% | 719 |
|
|
2021
Q3 | $226K | Buy |
1,739
+260
| +18% | +$39.3K | ﹤0.01% | 704 |
|
|
2021
Q2 | $263K | Buy |
1,479
+139
| +10% | +$24.1K | ﹤0.01% | 677 |
|
|
2021
Q1 | $220K | Sell |
1,340
-100
| -7% | -$16.5K | ﹤0.01% | 683 |
|
|
2020
Q4 | $238K | Hold |
1,440
| – | – | ﹤0.01% | 639 |
|
|
2020
Q3 | $205K | Buy |
+1,440
| New | +$179K | ﹤0.01% | 637 |
|
|
2020
Q1 | – | Sell |
-1,340
| Closed | -$200K | – | 695 |
|
|
2019
Q4 | $200K | Buy |
+1,340
| New | +$182K | ﹤0.01% | 677 |
|
|
2017
Q3 | – | Sell |
-1,380
| Closed | -$215K | – | 679 |
|
|
2017
Q2 | $215K | Sell |
1,380
-240
| -15% | -$36.7K | ﹤0.01% | 630 |
|
|
2017
Q1 | $235K | Buy |
+1,620
| New | +$211K | ﹤0.01% | 603 |
|
|
2016
Q4 | – | Sell |
-1,802
| Closed | -$219K | – | 640 |
|
|
2016
Q3 | $219K | Sell |
1,802
-115
| -6% | -$15.5K | ﹤0.01% | 587 |
|
|
2016
Q2 | $271K | Sell |
1,917
-130
| -6% | -$19.2K | 0.01% | 554 |
|
|
2016
Q1 | $267K | Sell |
2,047
-40
| -2% | -$4.98K | 0.01% | 538 |
|
|
2015
Q4 | $293K | Sell |
2,087
-93
| -4% | -$12.9K | 0.01% | 541 |
|
|
2015
Q3 | $290K | Sell |
2,180
-50
| -2% | -$8.61K | 0.01% | 531 |
|
|
2015
Q2 | $393K | Sell |
2,230
-20
| -0.9% | -$3.59K | 0.01% | 502 |
|
|
2015
Q1 | $389K | Buy |
2,250
+135
| +6% | +$23.2K | 0.01% | 507 |
|
|
2014
Q4 | $346K | Buy |
+2,115
| New | +$351K | 0.01% | 507 |
|
Other funds holding JAZZ
VPM
VCM
EC
Pinnacle Associates's JAZZ Position: Q1 2026 in Review
Pinnacle Associates reduced its Jazz Pharmaceuticals (JAZZ) stake by 4.5% in Q1 2026, selling an estimated $89K and leaving 10,694 shares worth $2.02M. The position accounts for 0.03% of the portfolio, ranked #396.
Pinnacle Associates first reported a position in JAZZ in Q4 2014 and has held it in 34 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Pinnacle Associates held 10,694 shares of Jazz Pharmaceuticals worth $2.02M as of Q1 2026.
- Pinnacle Associates sold 509 Jazz Pharmaceuticals shares in Q1 2026, an estimated $89K.
- Jazz Pharmaceuticals made up 0.03% of Pinnacle Associates's portfolio in Q1 2026, its #396 holding.
- Pinnacle Associates first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 34 quarters since.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.